Rigel Pharmaceuticals INC Form 4 insider transactions

Rigel Pharmaceuticals EVP, Chief Medical Officer Alison L. Hannah acquired 24,400 shares of common stock through the vesting of Restricted Stock Units.

Rigel Pharmaceuticals Director Kamil Ali-Jackson sold 2,500 shares of common stock on June 22, 2026, as part of a pre-arranged 10b5-1 trading plan to cover tax withholding obligations.

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, exercised stock options and adjusted common stock holdings, reflecting a recent reverse stock split.

EVP and Chief Commercial Officer David A. Santos disposed of 874 shares of Rigel Pharmaceuticals common stock to cover tax obligations.

Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, reported the disposition of 850 shares of common stock.

CEO Raul R. Rodriguez disposed of 2,424 shares of Rigel Pharmaceuticals common stock to satisfy tax withholding obligations.

Raymond J. Furey, EVP and General Counsel of Rigel Pharmaceuticals, disposed of 877 shares of common stock to cover tax obligations.

Director Kamil Ali-Jackson sold 2,500 shares of Rigel Pharmaceuticals common stock on May 26, 2026.

Director Jane Wasman acquired 5,750 shares of Rigel Pharmaceuticals common stock via a restricted stock unit vesting.

Director Walter Moos acquired 5,750 shares of Rigel Pharmaceuticals common stock via a restricted stock unit vesting.

Rigel Pharmaceuticals director Michael Patrick Miller acquired 5,750 shares of common stock via a restricted stock unit award.

Director Anthony Gregg LaPointe acquired 5,750 shares of Rigel Pharmaceuticals common stock via a restricted stock unit award.

Director Alison L. Hannah acquired 5,750 shares of Rigel Pharmaceuticals common stock through a restricted stock unit vesting.

Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units as part of his board compensation.

Rigel Pharmaceuticals director Kamil Ali-Jackson was granted 5,750 restricted stock units as part of board compensation.

Rigel Pharmaceuticals Director Walter H. Moos exercised stock options and subsequently sold 4,000 shares of common stock for $36.36 per share.

Rigel Pharmaceuticals' EVP, General Counsel, CCO & Corporate Secretary, Raymond J. Furey, was granted 19,497 Restricted Stock Units.

Rigel Pharmaceuticals' EVP, Chief Medical Officer Lisa Rojkjaer, was granted 18,894 shares of common stock through a Restricted Stock Unit award.

Rigel Pharmaceuticals CEO and President Raul R. Rodriguez was granted 53,915 Restricted Stock Units, vesting quarterly over three years starting March 31, 2026.

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, was granted 20,636 Restricted Stock Units, vesting quarterly over three years starting March 31, 2026.

Rigel Pharmaceuticals' EVP, Chief Commercial Officer, David A. Santos, was granted 19,430 shares of common stock through a Restricted Stock Unit award.

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, disposed of 3,546 common shares at $34.62 each to cover tax liabilities.

Rigel Pharmaceuticals' EVP, General Counsel, CCO & Corporate Secretary, Raymond J. Furey, disposed of 3,546 shares of common stock to cover tax liabilities.

Rigel Pharmaceuticals' EVP, Chief Commercial Officer, David A Santos, disposed of 3,546 shares of common stock to cover tax liabilities.

Rigel Pharmaceuticals CEO Raul R. Rodriguez reported a disposition of 7,607 common shares for tax obligations related to equity compensation.

Rigel Pharmaceuticals' EVP and Chief Medical Officer, Lisa Rojkjaer, disposed of 3,758 shares of common stock at $34.62 per share under a pre-arranged 10b5-1 plan.

Rigel Pharmaceuticals' EVP, Chief Commercial Officer, David A. Santos, disclosed a future non-discretionary disposition of 5,718 common shares for tax withholding purposes, effective February 2, 2026.

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, disposed of 5,488 common shares to cover tax withholding, retaining 59,247 shares.

Rigel Pharmaceuticals' EVP Raymond Furey reported a future disposition of 3,968 common shares at $36.01 to cover tax liabilities, part of a pre-planned Rule 10b5-1 transaction.

Rigel Pharmaceuticals CEO Raul R. Rodriguez reported exercising stock options and selling shares to cover tax obligations.